Description: CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
Home Page: www.canbridgepharma.com
Timeloit
Beijing,
China
Phone:
86 10 8414 8018
Officers
| Name | Title |
|---|---|
| Dr. James Qun Xue M.B.A., Ph.D. | Founder, Chairman, CEO & Member of Strategic Advisory Board |
| Mr. Glenn Hassan | Chief Financial Officer |
| Ms. Isabella Y. Zhao | Director of Investor Relations |
| Ms. Qian Ma | Head of Legal and Compliance & Joint Company Sec. |
| Ms. Stella Mao | Director of Public Affairs |
| Ms. Chris Chen | Sr. Director of HR |
| Mr. Yunxiang Zhu Ph.D. | VP & Head of Global Research |
| Dr. Gerald F. Cox M.D., Ph.D. | Chief Devel. Strategist & Interim Chief Medical Officer |
| Mr. Marcelo Cheresky | Chief Bus. Officer |
| Dr. Wei Zhang | Director & China Head of CMC Department |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Capital Goods |
| GIC Industry: | Trading Companies & Distributors |
| GIC Sub-Industry: | Trading Companies & Distributors |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0912 |
| Price-to-Sales TTM: | 4.7658 |
| IPO Date: | 2001-09-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 118 |